8-K: ADMA Biologics Appoints KPMG as New Independent Auditor

ADMA Biologics has engaged KPMG as its new independent registered public accounting firm, effective after the filing of the Q3 2024 report.

Summary

• ADMA Biologics has appointed KPMG LLP as their new independent registered public accounting firm.
• The engagement of KPMG will be effective upon the filing of the company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024.
• KPMG will audit the company's consolidated financial statements for the fiscal year ending December 31, 2024.
• The audit will be included in the company's Annual Report on Form 10-K, which is expected to be filed on or before March 3, 2025.
• ADMA Biologics did not consult with KPMG on accounting principles or audit opinions prior to this engagement.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate procedure, the appointment of a new auditor, which is generally viewed neutrally to positively. The selection of a reputable firm like KPMG is a positive sign.

Positives

• The appointment of a reputable firm like KPMG as the independent auditor could enhance investor confidence.
• The engagement of a new auditor is a standard corporate governance practice.

Risks

• The change in auditors could potentially lead to increased scrutiny of the company's financials.
• There is a risk of delays in the audit process, although the filing date is set for March 3, 2025.

Future Outlook

The company anticipates filing its Annual Report on Form 10-K on or before March 3, 2025, which will include the audited financial statements by KPMG.

Management Comments

• Adam S. Grossman, President and Chief Executive Officer, signed the report on behalf of ADMA Biologics.

Industry Context

The appointment of a new auditor is a routine corporate event, and the selection of KPMG is consistent with industry standards for publicly traded companies.

Comparison to Industry Standards

• Many publicly traded companies, such as Amgen, CSL Behring, and Grifols, use large, reputable firms like KPMG, Deloitte, Ernst & Young, or PwC for their audits.
• The transition to a new auditor is a common practice and does not indicate any unusual circumstances.

Stakeholder Impact

• Shareholders may view the appointment of KPMG positively, as it is a reputable firm.
• The change in auditors is not expected to have a significant impact on employees, customers, or suppliers.

Next Steps

• KPMG will begin its engagement after the filing of the Q3 2024 report.
• KPMG will audit the company's financial statements for the year ending December 31, 2024.
• The company will file its Annual Report on Form 10-K on or before March 3, 2025.

Key Dates

Keywords

auditor, KPMG, accounting, financial statements, ADMA Biologics, audit